Market Overview:
The global dysthymia clinical trial market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of dysthymia, rising awareness about available treatment options, and growing demand for novel therapies. The global dysthymia clinical trial market is segmented by type into drugs and others. The drugs segment is further sub-segmented into antidepressants and mood stabilizers. The antidepressants segment accounted for the largest share of the global dysthymia clinical trial market in 2017 owing to their high efficacy in treating symptoms of dysthymia. The others segment includes cognitive behavior therapy (CBT) and psychotherapy. The global dysthymia clinical trial market is also divided by application into hospitals, ambulatory surgical centers, and others (including clinics, research institutes, etc.). However ,the ambulatory surgical centers segmentis projectedtogrow at a higher CAGR duringthe forecast perioddue tot he increasing preferencefor outpatient care overinpatientcare .
Product Definition:
A dysthymia clinical trial is a study to test the effectiveness of a new drug or treatment for dysthymia, a type of chronic depression. Dysthymia can be difficult to treat, so it's important to test new treatments in order to find the best possible options for people who suffer from it.
Drugs:
Dysthymia is a chronic illness characterized by symptoms such as low mood, emotional distress and/or irritability. The disorder can be treated with various drugs; however, the treatment may not be as effective or efficient as desired. There remains a significant unmet need for Dysthymic Disorder (DD) based clinical trials in order to further understand its pathophysiology and develop more targeted treatments that will improve patient outcomes.
Others:
Others is a term used for all the other medical conditions that patients may be experiencing at the same time as the target disease. It includes symptoms such as Fatigue, Concentration difficulties, Headaches and Insomnia which are not due to dysthymia but may be related to it. Others also include general medical conditions such as infections and cardiovascular diseases that could have any relation with dysthymia or mood disorders.
Application Insights:
The others segment held the largest market share of dysthymia clinical trials in 2017. This segment includes research studies that are conducted in out-patient settings and do not involve patients with depression. The drugs segment is expected to grow at a faster rate during the forecast period as compared to other applications. Drugs used for treating depression include SSRIs, SNRIs, tricyclic antidepressants (TCAs), and MAOIs among others.
Dysthymia was one of the most common diagnoses made by mental health professionals across all income groups worldwide in 2016 according to WHO data.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing geriatric population and awareness about mental health disorders. In addition, availability of effective treatment in this region is one of the major factors responsible for Dysthymia clinical trial market growth.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure and growing target population base especially in India & China. Furthermore, government initiatives coupled with increased funding from private organizations are expected to fuel regional Dysthymia clinical trial markets during the same period. For instance, ‘India’s First Phase II/III Open Label Clinical Trial for Treatment of Major Depression Disorder’ was conducted by Tata Institute for Fundamental Research (TIFR).
Growth Factors:
- Increasing prevalence of dysthymia
- Growing awareness about dysthymia and its treatment options
- Rising demand for better and more effective treatments for dysthymia
- Availability of new and innovative therapies for dysthymia
- Growing number of clinical trials being conducted on dysthymia
Scope Of The Report
Report Attributes
Report Details
Report Title
Dysthymia Clinical Trial Market Research Report
By Type
Drugs, Others
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Sanofi, Auckland UniServices, Columbia Northwest Pharmaceuticals, New York State Psychiatric Institute, University Of Washington, Centre For Addiction And Mental Health, University Hospital Freiburg, University Of Barcelona, St.Luke’S-Roosevelt Hospital Center, Sheba Medical Center, University Of California, Oregon Health & Science University, Sunnybrook Health Sciences Centre
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Dysthymia Clinical Trial Market Report Segments:
The global Dysthymia Clinical Trial market is segmented on the basis of:
Types
Drugs, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Auckland UniServices
- Columbia Northwest Pharmaceuticals
- New York State Psychiatric Institute
- University Of Washington
- Centre For Addiction And Mental Health
- University Hospital Freiburg
- University Of Barcelona
- St.Luke’S-Roosevelt Hospital Center
- Sheba Medical Center
- University Of California
- Oregon Health & Science University
- Sunnybrook Health Sciences Centre
Highlights of The Dysthymia Clinical Trial Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dysthymia Clinical Trial Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A dysthymia clinical trial is a study that evaluates the effectiveness of a new treatment for dysthymia.
Some of the major players in the dysthymia clinical trial market are Sanofi, Auckland UniServices, Columbia Northwest Pharmaceuticals, New York State Psychiatric Institute, University Of Washington, Centre For Addiction And Mental Health, University Hospital Freiburg, University Of Barcelona, St.Luke¢â‚¬â„¢S-Roosevelt Hospital Center, Sheba Medical Center, University Of California, Oregon Health & Science University, Sunnybrook Health Sciences Centre.
The dysthymia clinical trial market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dysthymia Clinical Trial Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dysthymia Clinical Trial Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dysthymia Clinical Trial Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dysthymia Clinical Trial Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dysthymia Clinical Trial Market Size & Forecast, 2018-2028
4.5.1 Dysthymia Clinical Trial Market Size and Y-o-Y Growth
4.5.2 Dysthymia Clinical Trial Market Absolute $ Opportunity
Chapter 5 Global Dysthymia Clinical Trial Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dysthymia Clinical Trial Market Size Forecast by Type
5.2.1 Drugs
5.2.2 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dysthymia Clinical Trial Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dysthymia Clinical Trial Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dysthymia Clinical Trial Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dysthymia Clinical Trial Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dysthymia Clinical Trial Analysis and Forecast
9.1 Introduction
9.2 North America Dysthymia Clinical Trial Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dysthymia Clinical Trial Market Size Forecast by Type
9.6.1 Drugs
9.6.2 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dysthymia Clinical Trial Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dysthymia Clinical Trial Analysis and Forecast
10.1 Introduction
10.2 Europe Dysthymia Clinical Trial Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dysthymia Clinical Trial Market Size Forecast by Type
10.6.1 Drugs
10.6.2 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dysthymia Clinical Trial Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dysthymia Clinical Trial Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dysthymia Clinical Trial Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dysthymia Clinical Trial Market Size Forecast by Type
11.6.1 Drugs
11.6.2 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dysthymia Clinical Trial Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dysthymia Clinical Trial Analysis and Forecast
12.1 Introduction
12.2 Latin America Dysthymia Clinical Trial Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dysthymia Clinical Trial Market Size Forecast by Type
12.6.1 Drugs
12.6.2 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dysthymia Clinical Trial Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dysthymia Clinical Trial Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dysthymia Clinical Trial Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dysthymia Clinical Trial Market Size Forecast by Type
13.6.1 Drugs
13.6.2 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dysthymia Clinical Trial Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dysthymia Clinical Trial Market: Competitive Dashboard
14.2 Global Dysthymia Clinical Trial Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Auckland UniServices
14.3.3 Columbia Northwest Pharmaceuticals
14.3.4 New York State Psychiatric Institute
14.3.5 University Of Washington
14.3.6 Centre For Addiction And Mental Health
14.3.7 University Hospital Freiburg
14.3.8 University Of Barcelona
14.3.9 St.Luke’S-Roosevelt Hospital Center
14.3.10 Sheba Medical Center
14.3.11 University Of California
14.3.12 Oregon Health & Science University
14.3.13 Sunnybrook Health Sciences Centre
